Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Gjerstorff, Morten F ^a   Pøhl, Mette ^a,b   Olsen, Karen E ^a,b   Ditzel, Henrik J ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer testis antigen; GAGE; Immunotherapy; Lung cancer; NY ESO 1; SP17

Indexed keywords

CANCER TESTIS ANTIGEN; PROTEIN GAGE; PROTEIN NY ESO 1; PROTEIN SP17; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; TUMOR BIOPSY;

ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; NEOPLASM STAGING; PROGNOSIS; TESTIS;

EID: 84885016612     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-466     Document Type: Article

References (28)

1. Gjerstorff MF, Burns J, Ditzel HJ. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment. Expert Opin Biol Ther 2010, 10(7):1061-1075. 10.1517/14712598.2010.485188, 20420535.
2. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005, 5(8):615-625. 10.1038/nrc1669, 16034368.
3. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100(11):2014-2021. 10.1111/j.1349-7006.2009.01303.x, 19719775.
4. Rao M, Chinnasamy N, Hong JA, Zhang Y, Zhang M, Xi S, Liu F, Marquez VE, Morgan RA, Schrump DS. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res 2011, 71(12):4192-4204. 10.1158/0008-5472.CAN-10-2442, 3116976, 21546573.
5. Kronig H, Hofer K, Conrad H, Guilaume P, Muller J, Schiemann M, Lennerz V, Cosma A, Peschel C, Busch DH, et al. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Int J Cancer 2009, 125(3):649-655. 10.1002/ijc.24414, 19444908.
6. Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 2005, 174(7):4415-4423. 2174604, 15778407.
7. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83(5):584-594.
8. Nakagawa K, Noguchi Y, Uenaka A, Sato S, Okumura H, Tanaka M, Shimono M, Ali Eldib AM, Ono T, Ohara N, et al. XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin Cancer Res 2005, 11(15):5496-5503. 10.1158/1078-0432.CCR-05-0216, 16061866.
9. Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M, Spagnoli GC. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer 2007, 120(2):337-343. 10.1002/ijc.22309, 17066423.
10. Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, Fukuda M, Old LJ, Oka M, Nakayama E. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. Int J Cancer 2012, 131(5):E649-E658. 10.1002/ijc.27359, 22109656.
11. Nakamura Y, Noguchi Y, Satoh E, Uenaka A, Sato S, Kitazaki T, Kanda T, Soda H, Nakayama E, Kohno S. Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity. Lung Cancer 2009, 65(1):119-122. 10.1016/j.lungcan.2008.12.020, 19193472.
12. Tsuji T, Altorki NK, Ritter G, Old LJ, Gnjatic S. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. J Immunol 2009, 183(7):4800-4808. 10.4049/jimmunol.0900903, 19734225.
13. Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Tureci O, Wiewrodt R, Barnes AC, Robertson JF. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008, 63(3):228-233. 10.1136/thx.2007.083592, 17932110.
14. Watanabe Y, LePage S, Elliott M, Secrist H, Tanaka T, Kawahara M, Matsumura A, Hosoe S, Ogawara M, Okada M, et al. Characterization of preexisting humoral immunity specific for two cancer-testis antigens overexpressed at the mRNA level in non-small cell lung cancer. Cancer Immun 2006, 6:3.
15. Shan Q, Lou X, Xiao T, Zhang J, Sun H, Gao Y, Cheng S, Wu L, Xu N, Liu S. A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. Cancer Lett 2013, 328(1):160-167. 10.1016/j.canlet.2012.08.019, 22922091.
16. Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specific cancer immunotherapeutic. Immunother 2009, 1(1):19-25.
17. Gjerstorff MF, Ditzel HJ. Limited SP17 expression within tumors diminishes its therapeutic potential. Tissue Antigens 2012, 80(6):523-527. 10.1111/tan.12015, 23137323.
18. Gjerstorff MF, Johansen LE, Nielsen O, Kock K, Ditzel HJ. Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. Br J Cancer 2006, 94(12):1864-1873. 10.1038/sj.bjc.6603163, 2361341, 16773077.
19. Gjerstorff MF, Kock K, Nielsen O, Ditzel HJ. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. Hum Reprod 2007, 22(4):953-960. 10.1093/humrep/del494, 17208940.
20. Shigematsu Y, Hanagiri T, Shiota H, Kuroda K, Baba T, Mizukami M, So T, Ichiki Y, Yasuda M, So T, et al. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer 2010, 68(1):105-110. 10.1016/j.lungcan.2009.05.010, 19545928.
21. Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, Miyamoto M, Morikawa T, Kondo S, Ikeda H, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 2006, 28(5):1089-1098.
22. Kim SH, Lee S, Lee CH, Lee MK, Kim YD, Shin DH, Choi KU, Kim JY, Park Do Y, Sol MY. Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung 2009, 187(6):401-411. 10.1007/s00408-009-9181-3, 19795170.
23. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001, 92(6):856-860.
24. Schettino C, Bareschino MA, Sacco PC, Maione P, Rossi A, Casaluce F, Sgambato A, Gridelli C. New molecular targets in the treatment of NSCLC. Current Pharma Design 2013, 19(30):5333-5343.
25. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res off J Am Assoc Cancer Res 2008, 14(13):4275-4283.
26. Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 2007, 25(3):707-711.
27. Carvalho RH, Haberle V, Hou J, van Gent T, Thongjuea S, van Ijcken W, Kockx C, Brouwer R, Rijkers E, Sieuwerts A, et al. Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenet Chrom 2012, 5(1):9.
28. Lokk K, Vooder T, Kolde R, Valk K, Vosa U, Roosipuu R, Milani L, Fischer K, Koltsina M, Urgard E, et al. Methylation markers of early-stage non-small cell lung cancer. PLoS One 2012, 7(6):e39813. 10.1371/journal.pone.0039813, 3387223, 22768131.